Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

verely affected HAE patients. It is also beneficial that this C1-inhibitor therapy is also to be approved for therapy of acute attacks and pre-procedure prevention."

"This positive CHMP opinion marks a key step in making Cinryze available to HAE patients across Europe and beyond that choose to proactively address their disease," commented Thierry Darcis, M.D., ViroPharma's vice president, general manager, Europe.  "We estimate that there are several thousand patients throughout Europe who suffer from this debilitating disease, and with this recommendation, these patients may soon benefit from the unique use of Cinryze to either prevent their attacks or treat them when they occur, with the added convenience of self administration after appropriate training.  ViroPharma is committed to providing important medicines to patients with unmet medical needs, and we look forward to working closely with physicians across Europe toward this important goal."

The CHMP is the scientific advisory body of the EMA responsible for reviewing Marketing Authorization Applications for medicinal products for human use.  The CHMP positive opinion forms the scientific basis for the European Commission to issue a binding decision for a Centralized Marketing Authorization, once issued, is valid throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein. The anticipated timeframe for the European Commission decision is in the second quarter of 2011.  A summary of the CHMP opinion will be available here: http://tinyurl.com/2am4ubc.  Please select "C" to access the Cinryze summary opinion.

Continued Darcis, "Our work is already well underway towards preparing for our commercial launch in Europe, with the goal of making this important therapeutic product available to European patients as soon as possible."

Cinryze w
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... quarter financial results on Tuesday, July 29, 2014, after the ... followed by a conference call with the investment community at ... be Robert A. Bradway , chairman and chief executive ... Live audio of the conference call will be simultaneously ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists who ... do to ensure that their practice will be a success. ... basic supplies they use the most can make all the ... dentists have recently discovered that purchasing discount dental supplies ... According to successful dentists across the ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2Dental Supplies Online is Key to Dental Success...Really! 2
... 1, 2012 The FDA and representatives from the ... on proposed recommendations for the third reauthorization of a ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The recommendations would authorize the ... five years, plus adjustments for inflation. Details of the ...
... Corporation (NYSE: BSX ) announces first ... PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent ... the new device was performed by Professor Antonio ... at Columbus Hospital and San Raffaele Hospital in ...
Cached Medicine Technology:FDA and Industry Reach Agreement in Principle on Medical Device User Fees 2FDA and Industry Reach Agreement in Principle on Medical Device User Fees 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 4
(Date:7/25/2014)... 25, 2014 Health Advocate™, Inc., the ... subsidiary of West Corporation, is introducing its newest solution ... Costs and Enhance Quality. , The webinar will be ... ET and again at 2 PM ET. For more ... http://www.HealthAdvocate.com/Analytics or call 866.799.2655. , In an ...
(Date:7/25/2014)... could be treated more quickly after Manchester research ... and blood test on arrival, is effective in ... new study shows., The findings of a research ... Journal, could potentially make a huge difference to ... the most common reason for emergency hospital admission. ...
(Date:7/25/2014)... A probiotic that prevents obesity could be on ... in the gut inhibit weight gain, insulin resistance ... in mice, Vanderbilt University investigators have discovered. , ... to human," said senior investigator Sean Davies, Ph.D., ... most of the negative consequences of obesity in ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
(Date:7/25/2014)... -- Dietary changes can dramatically alter the balance of ... to a new study. These fluctuations could ... ease flare-ups for people with certain chronic illnesses, such ... the researchers said. Trillions of bacteria live in ... isn,t well understood, the Massachusetts Institute of Technology (MIT) ...
Breaking Medicine News(10 mins):Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2
... 2.1 Million Teens ... ... 2009 -- With an estimated 2,500 children ages 12 to 17 taking a prescription painkiller ... with MedSafe, the developers of a state-of-the-art medication lock-box, to curb the problem where it ...
... worker study suggests more potential hazards from the plastics ... to high levels of the controversial plastics chemical bisphenol ... including impotence and low sex drive, among Chinese factory ... researchers stressed that the workers were exposed to BPA ...
... ... is the inspiration for a new film which will find its way onto the ... ... event, the Molecular Medicine Tri-Conference (February 3-5, 2010) will feature inspirational Keynote John F. ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... LONDON, November 11 Extensive research conducted ... University of,Sheffield on the Simbionix PROcedure Rehearsal Studio(TM), was ... 2009 congress in Lisbon, Portugal. , ... year, is,the world,s first patient specific system to enable ...
... ... home or office using methods and products that are government-approved, but that won,t harm your ... Rhinebeck, ... The Natural Flu Protection Kit, the first product to emerge from the company’s partnership with ...
Cached Medicine News:Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 2Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 3Health News:BPA Tied to Impotence in Men 2Health News:BPA Tied to Impotence in Men 3Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 2Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: